CNBC December 7, 2023
Key Points
– The Biden administration asserted its authority to seize the patents of certain costly medications.
– The effort marks a new push to slash high drug prices and promote more competition in the pharmaceutical industry in the U.S.
– The administration unveiled a new framework outlining the factors federal agencies should consider in determining whether to use a controversial policy known as march-in rights
The Biden administration on Thursday opened the door to seizing the patents of certain costly medications from drugmakers in a new push to slash high drug prices and promote more pharmaceutical competition.
The administration unveiled a framework outlining the factors federal agencies should consider in deciding whether to use a controversial policy, known as...
Today's Sponsors
Today's Sponsor